Method for evaluating preventing effect of drug on viral pneumonia

A technology for viral pneumonia and pneumonia, which is applied in the field of drug evaluation and screening, can solve problems such as high technical requirements, large surgical trauma, and heavy workload, and achieve the effects of high egg production, short development cycle, and strong comparability
CN112106705AActive Publication Date: 2020-12-22北京环特智鱼优检生物科技有限公司
8 Cites 2 Cited by

Patent Information

Authority / Receiving Office
CN · China
Current Assignee / Owner
北京环特智鱼优检生物科技有限公司
Publication Date
2020-12-22

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The invention relates to the technical field of drug evaluation and screening, discloses a method for establishing a pneumonia animal model, and provides a method for evaluating a preventing effect ofa drug on viral pneumonia by reasonably adopting the model to solve the problems that an existing pneumonia evaluation animal model is complex in modeling operation and not beneficial to subsequent evaluation and screening work of a pneumonia treatment drug. The pneumonia animal model is established by placing zebra fishes of 5dpf in water for culturing and injecting a pneumonia inducer poly(I:C)into the zebra fishes, wherein the administration concentration is greater than or equal to 50 ng per zebra fish; and indexes are evaluated by adopting the inflammatory regression effect, the macrophage improvement effect and the related gene RNA relative expression quantity effect during drug evaluation. The pneumonia model can be used for evaluating the toxicity or efficacy of known drugs can be further used for screening unknown drugs, the real situation of the drugs in vivo can be accurately reflected, in-vivo high-throughput screening or evaluating of the treatment effect of the drugs onviral pneumonia can be realized, and the advantages of reliability, rapidness, high efficiency, low cost, high cost performance and the like are achieved.
Need to check novelty before this filing date? Find Prior Art

Description

technical field

[0001] The invention relates to the technical field of drug evaluation and screening, in particular to a method for evaluating the effect of drugs on preventing viral pneumonia. Background technique

[0002] In non-bacterial pneumonia, viral pneumonia accounts for 25%-50%, and it is often aspiration infection. The main source of infection is the patient. It is transmitted through droplets and close contact. It occurs in eruptive viral infection, often accompanied by trachea-bronchial infection, mostly occurs in winter and spring, can be sporadic or popular, and is more common in infants, the elderly, and patients with existing chronic cardiopulmonary diseases. Among them, influenza virus is the most common pathogen of viral pneumonia in adults and the elderly, while viral pneumonia in infants and young children is often caused by respiratory syncytial virus infection. Others such as parainfluenza virus, cytomegalovirus, coronavirus, adenovirus, rhinovirus an...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More